Manufacturing sterile injectables today is more complex than ever. Navigating stringent aseptic requirements, evolving regulatory expectations and the need for significant specialized investment has made the path to market increasingly challenging.
A fragmented approach across development, drug substance manufacturing and fill finish remains a common industry practice that can introduce critical vulnerabilities. With every handoff, the risks multiply: the potential for contamination increases, tech transfer misalignments can cause delays, regulatory compliance becomes more complicated and supply chains grow more difficult to manage. As these issues compound, they create delays that slow timelines and impact patients’ access to potentially critical therapies.
Kindeva’s Bridgeton facility is purpose-built to change that. Bringing together advanced isolator technology, flexible filling formats, real-time automation and integrated services under one roof, Bridgeton offers a streamlined, scalable and Annex 1-compliant solution to bring complex injectable products to market more efficiently.
In this eBook, you will discover how Bridgeton was purpose-built for progress with:
- Isolator technology and automated filling lines
- Integrated fill finish, device manufacturing and final packaging in one facility
- Scalability from clinical trial batches to full-scale commercial supply
- Annex 1-compliant infrastructure
With over 155,000 square feet of cGMP aseptic operations space, 150 million unit annual capacity and world-class sterile manufacturing technology, Bridgeton is designed to deliver excellence throughout your injectable project.
Download the Bridgeton eBook to explore how we can transform tomorrow together at our world-class sterile fill finish facility today!
Ready to find out what a true CDMO partnership feels like? Let us show you how our world-class facilities, technologies and analytical capabilities can provide your project with strategic value that bridges beyond manufacturing.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Sterile product introduction and tech transfers in a crowded market
The tech transfer landscape for sterile products is increasingly complex, with pressure to reduce time to market. Find out how to navigate common challenges and avoid costly delays or oversights in this presentation from our Director, Client Portfolio & Relationship Management, Kim Brown. Download your copy to explore: Benefits of a commercial manufacturing mindset How […]
Learn More
Aseptic injectable fill-finish facility
Through strategic investments and expansions, Kindeva Drug Delivery is on the forefront of combination product innovation. Our aseptic injectable fill-finish facility in Bridgeton, Missouri, is one example of our commitment to excellence. With the addition of this facility, we are one of only a few CDMOs capable of servicing sterile fill, device manufacture, and final […]
Learn More
Missed our PDA poster presentations? Unlock injectable & intradermal insights
Access the Presentations At the 2024 PDA Annual Meeting, experts from Kindeva Drug Delivery presented our insights on injectable and intradermal drug-device combination products. Spanning holistic design for aseptic injectable fill-finish, human factors for autoinjectors, and manufacturing of microneedle array patches (MAPs), our posters showcase our latest developments and know-how across injectable drug delivery. If […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.